Skip to content

Evaluation study on the trial consumption of ginseng whole ingredient oral solution by middle-aged and old-aged volunteers of forest ginseng (25 years)

Evaluation study on the trial consumption of ginseng whole ingredient oral solution by middle-aged and old-aged volunteers of forest ginseng (25 years)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000386
Enrollment
Unknown
Registered
2025-02-24
Start date
2024-12-22
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy people

Interventions

treatment group:Forest-grown ginseng whole ingredient oral solution 50ml each 1 capsule per day each capsule contains 3g of ginseng raw material

Sponsors

Affiliated Hospital of Changchun University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Obtained informed consent; (2) Age =45 years and <75 years; (3) Ability to comply with the trial process. (4) Have sufficient cognitive ability to sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients who have difficulty taking oral medications due to underlying diseases etc; (2) With serious underlying diseases affecting survival including uncontrolled clinically significant cardiac pulmonary renal gastrointestinal haematological neuropsychiatric immunological metabolic diseases malignant tumours and severe malnutrition; (3) Allergic allergic to the products involved in the treatment programme; (4) Suffering from hypertension coronary heart disease diabetes mellitus hyperlipidaemia and other diseases that are not well controlled by drugs; (5) Impact on the intestinal flora including the use of drugs that may have an impact on the intestinal flora within 4 weeks prior to enrolment or taking probiotics on a daily basis suffering from inflammatory bowel disease severe intestinal obstruction that does not allow access to the faeces and so on; (6) People who in the judgement of the investigator are not suitable for the use of products involved in the treatment protocol. (7) Pregnant or lactating women; (8) People whose mental state is unable to co-operate who suffer from psychiatric illnesses who have no self-awareness or who are unable to express themselves clearly; (9) Those who are participating in other clinical trials; patients who in the judgement of the investigator will experience enrolment complications or poor compliance that will affect the assessment of efficacy and safety.

Design outcomes

Primary

MeasureTime frame
Fatigue scale;Information collection of four TCM diagnoses;Waist-hip ratio;Sleep quality;Glycosylated hemoglobin;Total cholesterol;Abdominal girth;High density lipoprotein;Systolic blood pressure;Low-density lipoprotein;Cognitive function;BMI;Diastolic blood pressure;waistline;triglyceride;Pulse pressure;Fasting blood glucose;

Secondary

MeasureTime frame
Active ingredient metabolic process in vivo;Glucose assay;Carotid ultrasound;pwv;Sleep diary;Brachial artery flow-mediated dilation;Body composition analysis and energy metabolism test;Hypersensitive C-reactive protein;

Countries

China

Contacts

Public ContactJixiang Ren

Affiliated Hospital of Changchun University of Traditional Chinese Medicine

renjx2003@163.com13604324381

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026